Table 1 Baseline demographics and clinical characteristics at diagnosis of metastatic breast cancer
Variables | Overall | Eribulin | Noneribulin | P value Fisher’s exact test | |||
|---|---|---|---|---|---|---|---|
(N = 293) | (N = 66) | (N = 227) | |||||
Median age, years (range) | 54.0 (25–78) | 55.0 (27–77) | 54.0 (25–78) | ||||
Diagnosis, n (%) | |||||||
Metastatic | 214 | (73.0) | 44 | (66.7) | 170 | (74.9) | 0.21 |
Locally advanced | 79 | (27.0) | 22 | (33.3) | 57 | (25.1) | |
Sites of metastases, n (%) | |||||||
Lung | 71 | (24.2) | 16 | (24.2) | 55 | (24.2) | 1.00 |
Liver | 58 | (19.8) | 20 | (30.3) | 38 | (16.7) | 0.02* |
Bone | 155 | (52.9) | 35 | (53.0) | 120 | (52.9) | 1.00 |
CNS | 14 | (4.8) | 3 | (0.5) | 11 | (4.8) | 1.00 |
Soft tissue | 185 | (63.2) | 44 | (66.7) | 141 | (62.1) | 0.56 |
Treatment regimens, n (%) | |||||||
Anthracycline-based regimen for EBC | 79 | (27.0) | 22 | (33.3) | 57 | (25.1) | |
Anthracycline-based regimen for MBC | 135 | (46.1) | 26 | (39.4) | 109 | (48.0) | |
Taxane-based regimen for EBC | 39 | (13.3) | 18 | (27.3) | 21 | (9.3) | |
Taxane-based regimen for MBC | 228 | (77.8) | 53 | (80.3) | 175 | (77.1) | |
Eribulin as first-/second-line for MBC | 31 | (47.0) | 31 | (47.0) | – | ||
Taxane-based regimen prior to eribulin | 40 | (13.7) | 40 | (60.6) | – | ||